These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

286 related items for PubMed ID: 23811702

  • 1. Sequencing systemic therapies in metastatic castration-resistant prostate cancer.
    Liu JJ, Zhang J.
    Cancer Control; 2013 Jul; 20(3):181-7. PubMed ID: 23811702
    [Abstract] [Full Text] [Related]

  • 2. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
    Nuhn P, De Bono JS, Fizazi K, Freedland SJ, Grilli M, Kantoff PW, Sonpavde G, Sternberg CN, Yegnasubramanian S, Antonarakis ES.
    Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
    [Abstract] [Full Text] [Related]

  • 3. Current management of advanced and castration resistant prostate cancer.
    Gomella LG, Petrylak DP, Shayegan B.
    Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
    [Abstract] [Full Text] [Related]

  • 4. Castration-resistant prostate cancer: from new pathophysiology to new treatment.
    Sridhar SS, Freedland SJ, Gleave ME, Higano C, Mulders P, Parker C, Sartor O, Saad F.
    Eur Urol; 2014 Feb; 65(2):289-99. PubMed ID: 23957948
    [Abstract] [Full Text] [Related]

  • 5. Current therapeutic options in metastatic castration-resistant prostate cancer.
    Ingrosso G, Detti B, Scartoni D, Lancia A, Giacomelli I, Baki M, Carta G, Livi L, Santoni R.
    Semin Oncol; 2018 Oct; 45(5-6):303-315. PubMed ID: 30446166
    [Abstract] [Full Text] [Related]

  • 6. Sequencing Treatment for Castration-Resistant Prostate Cancer.
    Handy CE, Antonarakis ES.
    Curr Treat Options Oncol; 2016 Dec; 17(12):64. PubMed ID: 27822685
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Progress in the treatment of advanced prostate cancer.
    Sternberg CN, Petrylak DP, Madan RA, Parker C.
    Am Soc Clin Oncol Educ Book; 2014 Dec; ():117-31. PubMed ID: 24857068
    [Abstract] [Full Text] [Related]

  • 10. Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science.
    Nussbaum N, George DJ, Abernethy AP, Dolan CM, Oestreicher N, Flanders S, Dorff TB.
    Prostate Cancer Prostatic Dis; 2016 Jun; 19(2):111-21. PubMed ID: 26832363
    [Abstract] [Full Text] [Related]

  • 11. Practical guide to immunotherapy in castration resistant prostate cancer: the use of sipuleucel-T immunotherapy.
    Gomella LG, Gelpi-Hammerschmidt F, Kundavram C.
    Can J Urol; 2014 Apr; 21(2 Supp 1):48-56. PubMed ID: 24775724
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer.
    MacVicar GR, Hussain MH.
    Curr Opin Oncol; 2013 May; 25(3):252-60. PubMed ID: 23511665
    [Abstract] [Full Text] [Related]

  • 14. Improvement in survival and quality of life with new therapeutic agents in metastatic castration-resistant prostate cancer: comparison among the results.
    Recine F, Ceresoli GL, Baciarello G, Cerbone L, Calabrò F.
    Q J Nucl Med Mol Imaging; 2015 Dec; 59(4):400-10. PubMed ID: 26337241
    [Abstract] [Full Text] [Related]

  • 15. Challenges in the sequencing of therapies for the management of metastatic castration-resistant prostate cancer.
    Parente P, Parnis F, Gurney H.
    Asia Pac J Clin Oncol; 2014 Sep; 10(3):205-15. PubMed ID: 24750803
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Emerging agents for the therapy of advanced prostate cancer.
    Hathaway AR, Baker MK, Sonpavde G.
    Future Oncol; 2015 Sep; 11(20):2775-87. PubMed ID: 26367474
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.
    Maughan BL, Xhou XC, Suzman DL, Nadal R, Bassi S, Schweizer MT, Antonarakis ES.
    Prostate; 2015 Nov; 75(15):1814-20. PubMed ID: 26306637
    [Abstract] [Full Text] [Related]

  • 20. Molecular alterations and emerging targets in castration resistant prostate cancer.
    Lorente D, De Bono JS.
    Eur J Cancer; 2014 Mar; 50(4):753-64. PubMed ID: 24418724
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.